引入一种基于聚合酶链反应检测板的新型脑脊液评估方法用于脑炎和脑膜炎：它是否会影响经验性治疗持续时间、住院时间和病原体特异性诊断？
Introducing a New Polymerase Chain Reaction Panel-Based Cerebrospinal Fluid Evaluation for Encephalitis and Meningitis: Does It Influence Empiric Treatment Duration, Length of Hospital Stay, and Pathogen-Specific Diagnoses?
作者信息
Sidler Fabian, Bittel Pascal, Marschall Jonas, Jent Philipp
机构信息
Department of Visceral Surgery and Medicine, Inselspital Bern University Hospital, University of Bern, Bern, Switzerland.
Institute for Infectious Diseases, University of Bern, Bern, Switzerland.
出版信息
Open Forum Infect Dis. 2025 Apr 24;12(5):ofaf241. doi: 10.1093/ofid/ofaf241. eCollection 2025 May.
We analyzed the impact of a diagnostic meningitis/encephalitis polymerase chain reaction panel. Introducing the test resulted in no significantly shortened empiric antibiotic streptococcal/meningococcal treatment (-1 day [95% confidence interval {CI}, 0-3 days]; = .16), nor hospitalization (-2 days [95% CI, 0-3 days]; = .86). Empiric treatment duration against Herpesviridae and remained unchanged, and pathogen-specific diagnoses were not increased.
我们分析了诊断性脑膜炎/脑炎聚合酶链反应检测板的影响。引入该检测并未显著缩短经验性抗生素治疗链球菌/脑膜炎球菌感染的疗程（缩短1天[95%置信区间{CI}，0 - 3天]；P = 0.16），也未缩短住院时间（缩短2天[95%CI，0 - 3天]；P = 0.86）。针对疱疹病毒科的经验性治疗疗程保持不变，且病原体特异性诊断并未增加。
Zotero 插件